


Bellevue Funds (Lux) -Bellevue Obesity Solutions I CHF - Accumulating / LU0415392835 / A0RPSR / Waystone M.Co.

Last 05/16/2024 ¹	Region	Branch	Type of yield	Type
464.56 CHF	Worldwide	Sector Biotechnology	reinvestment	Equity Fund

■ Bellevue Funds (Lux) -Bellevue Obesity Solutions I CHF - Accumulating
■ Benchmark: IX Aktien Biotechnologie



Risk key figures

SRI 1 2 3 4 5 6 7

Mountain-View Funds Rating²EDA³ 74

Yearly Performance

2023	-18.02%
2022	-10.14%
2021	+4.70%
2020	+13.08%
2019	+26.49%

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	5.00%	Minimum investment	UNT 0
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Biotechnology	Deposit fees	0.00%	UCITS / OGAW	Yes
Fund domicile	Luxembourg	Redemption charge	0.00%	Performance fee	0.00%
Tranch volume	-	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(05/16/2024) USD 36.73 mill.	Dividends		Investment company	
Launch date	4/2/2009	Waystone M.Co.(Lux)			
KESr report funds	Yes	19, rue de Bitbourg, 1273, Luxembourg			
Business year start	01.07.	Luxembourg			
Sustainability type	-	www.waystone.com			
Fund manager	Christian Lach, Lukas Leu, Oliver Kubli				

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	+4.84%	+15.80%	+16.97%	+0.54%	-0.39%	-11.16%	+13.89%	+271.65%
Performance p.a.	-	-	-	+0.54%	-0.20%	-3.87%	+2.63%	+9.06%
Sharpe ratio	8.44	3.03	4.88	-0.26	-0.22	-0.39	-0.05	0.21
Volatility	8.76%	10.11%	10.04%	12.74%	18.55%	19.69%	22.89%	24.74%
Worst month	-	-1.56%	-1.56%	-7.37%	-7.37%	-10.27%	-10.27%	-21.25%
Best month	-	6.08%	6.08%	6.08%	8.54%	8.54%	14.54%	14.54%
Maximum loss	-0.91%	-5.02%	-5.02%	-17.20%	-24.16%	-35.42%	-35.42%	-

Distribution permission

Austria, Germany, Switzerland, United Kingdom, Luxembourg

1 Important note on update status: The displayed date refers exclusively to the calculation of the NAV.

2 The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

3 Displays the Ethical-Dynamical Ratio calculated according to standard criteria. The maximum value is 100. For more information visit [EDA](#)

DISCLAIMER: The information on this page are for informational purposes only and should neither an offer to sell nor a solicitation for the purchase of the security or recommendation in favor of the security to be understood. baha GmbH assumes no liability despite thorough searches for the accuracy of the data.

Funds data from: [www.mountain-view.com](#). Fact Sheet created by: [www.baha.com](#)

Created: 05/20/2024

Bellevue Funds (Lux) -Bellevue Obesity Solutions I CHF - Accumulating / LU0415392835 / A0RPSR / Waystone M.Co.

Investment strategy


Without restricting the scope of the term "biotechnology", the companies within the entire value chain in the biotechnology sector consist especially of companies that prepare, develop, utilise, market and/or sell processes, methods, technologies and products in which organisms, cells or cell constituents are used. Up to one third of the net assets can be invested in debt securities of private and government issuers with various terms and credit ratings. The Fund may engage in derivative transactions in order to achieve an efficient portfolio management, in particular also for hedging purposes.

Investment goal


The Fund invests at least two thirds of the net assets of Bellevue Biotech in a portfolio of carefully chosen shares and other equity securities of companies in the biotechnology industry or companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries.

Assessment Structure


Assets




Largest positions



Countries



Branches



Currencies

